Home › NDC Lookup › Ingredients › Glipizide › 66112-0914-04
⚪image loading
(from DailyMed)

Glipizide 5 mg Tablet, 18,000-count — NDC 66112-914-04 (Billing 66112-0914-04)

by Piramal Pharma Limited · 18000 TABLET in 1 BOTTLE

This is a package of 18,000 tablets of Glipizide 5 mg Tablet from Piramal Pharma Limited, first listed with the FDA May 2017 and currently FDA-listed.

NDC 66112-0914-04
🏷️ FDA NDC (as labeled) 66112-914-04 billing pads the product segment with a zero
This package
Contains18,000-count Pack sizes4 compare ↓
FDA-listed Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Nov 19, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

NDC database record

One package, one record: these facts belong to NDC 66112-914-04 alone.

Record
FDA NDC Directory package listing · Drug for further processing
Code segments
66112 labeler · 914 product · 04 package
Package marketed since
May 1, 2017
Listing certified through
Dec 31, 2026
Barcode (UPC-A, from the NDC)
3 6611291404 9
FDA record last changed
Jul 24, 2026

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 66112-914-04
Product NDC 66112-914
11-digit billing NDC 66112091404
SPL Set ID b6dd1e45-d298-40f3-baf3-6c23365f5dcd
DEA schedule Non-controlled
Marketing category DRUG FOR FURTHER PROCESSING
Marketing status FDA-listed
FDA listing status Listed (active directory)
Marketing start 2017-05-01
Dosage form TABLET
Substance GLIPIZIDE
Why two NDCs? The FDA registers this code as 66112-914-04 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 66112-0914-04. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

Clinical

📗 Our plain-language guide HelloPharmacist
  • Glipizide helps lower your blood sugar by prompting your pancreas to release more insulin — especially after meals. It's used in type 2 diabetes alongside diet and exercise, not as...
  • What exactly is glipizide supposed to do for my diabetes?
  • The regular tablet works relatively quickly and is usually taken about 30 minutes before a meal. The extended-release tablet (including the brand Glucotrol XL) releases the medicin...
  • What's the difference between the regular tablet and the extended-release tablet?
📖 Read our full Glipizide guide →
1
Nutrient depletion considerations

Glipizide may be associated with lower levels of 1 nutrient — worth a chat with your pharmacist, not a cause for alarm.

An association is not a deficiency. Educational only — don't start or stop anything without professional guidance.
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eachPer package
Retail pharmacies payNADAC · weekly Not in the retail survey — common for institutional, discontinued, or low-volume packs.
Medicaid paysCMS SDUD · 12 mo No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data.
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
ℹ️
No price is published for this exact package yet. CMS surveys NADAC per package size, so a different pack of the same drug often has one.
Try another pack size: 100 tablets 500 tablets 1000 tablets
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
66112-0914-01 66112-914-01 Main listing 100 TABLET in 1 BOTTLE — — Active
66112-0914-02 66112-914-02 500 TABLET in 1 BOTTLE — — Active
66112-0914-03 66112-914-03 1000 TABLET in 1 BOTTLE — — Active
66112-0914-04 You're viewing this 18000 TABLET in 1 BOTTLE — — Active

You're viewing the largest of 4 pack sizes for this product.

Pack size FAQ

What quantity is in this package?
This is a 18,000-count package — 18000 tablet in 1 bottle.
How does this package differ from NDC 66112-0914-01?
Both are Glipizide 5 mg Tablet — the drug itself is identical. This page's package is the 18,000-count one, while NDC 66112-0914-01 is the 100 tablets package.
What NDC number is used to bill for this package of Glipizide 5 mg Tablet?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Glipizide 5 mg 60505-0141-00 Apotex 100 tablets $0.033 AB Availability likely —
Glipizide 5 mg 60687-0690-01 American 100 tablets $0.033 AB Availability likely —
Glipizide 5 mg 00591-0460-01 Actavis 100 tablets $0.033 — Availability likely —
Glipizide 5 mg 62559-0315-10 ANI 1000 tablets $0.033 AB Availability likely —
Glipizide 5 mg 68645-0574-54 Legacy 30 tablets $0.033 AB Availability likely —
Glipizide 5 mg 69584-0309-10 Oxford 100 tablets $0.033 AB Availability likely —
Glipizide 5 mg 50268-0361-15 AvPAK 50 tablets $0.033 AB Availability likely —
Glipizide 5 mg 00904-6637-61 Major 100 tablets $0.033 AB Availability likely —
Glipizide 5 mg 72888-0116-00 Advagen 1000 tablets $0.033 AB Availability likely —
Glipizide 5 mg 43353-0207-45 Aphena 45 tablets — AB FDA listed —
Glipizide 5 mg 71205-0041-30 Proficient 30 tablets — AB FDA listed —
Glipizide 5 mg 00615-8407-05 NCS 15 tablets — AB FDA listed —
Glipizide 5 mg 71610-0680-45 Aphena 45 tablets — AB FDA listed —
Glipizide 5 mg 51407-0620-10 Golden 1000 tablets — AB FDA listed —
Glipizide 5 mg 82804-0174-30 Proficient 30 tablets — AB FDA listed —
Glipizide 5 mg 55289-0806-93 PD-Rx 180 tablets — AB FDA listed —
Glipizide 5 mg 68071-4939-01 NuCare 100 tablets — AB FDA listed —
Glipizide 5 mg 71335-3133-01 Bryant 100 tablets — AB FDA listed —
Glipizide 5 mg 50090-7908-00 A-S 90 tablets — AB FDA listed —
Glipizide 5 mg 55154-7987-00 Cardinal 10 tablets — AB FDA listed —
Glipizide 5 mg 71335-2528-01 Bryant 100 tablets — AB FDA listed —
Glipizide 5 mg 71335-0930-01 Bryant 100 tablets — AB Discontinued —
Glipizide 5 mg 82804-0959-00 Proficient 100 tablets — AB FDA listed —
Glipizide 5 mg 63629-1398-01 Bryant 100 tablets — AB FDA listed —
Glipizide 5 mg 68788-0141-01 Preferred 100 tablets — AB FDA listed —
Glipizide 5 mg 71610-0175-60 Aphena 90 tablets — AB FDA listed —
Glipizide 5 mg 68071-4223-03 NuCare 30 tablets — AB FDA listed —
Glipizide 5 mg 72789-0464-86 PD-Rx 360 tablets — AB FDA listed —
Glipizide 5 mg 50090-7755-00 A-S 30 tablets — AB FDA listed —
Glipizide 5 mg 51655-0180-25 Northwind 60 tablets — AB FDA listed —
Glipizide 5 mg 68071-3548-06 NuCare 60 tablets — AB FDA listed —
Glipizide 5 mg 68788-8512-01 Preferred 100 tablets — AB FDA listed —
Glipizide 5 mgthis 66112-0914-04 Piramal 18000 tablets — — FDA listed —
Glipizide 5 mg 68071-4085-03 NuCare 30 tablets — AB FDA listed —
Glipizide 5 mg 68788-4020-01 Preferred 100 tablets — AB FDA listed —
Glipizide 5 mg 70518-0552-00 REMEDYREPACK 30 tablets — AB FDA listed —
Glipizide 5 mg 50090-6473-00 A-S 30 tablets — AB FDA listed —
Glipizide 5 mg 50090-7756-00 A-S 90 tablets — AB FDA listed —
Glipizide 5 mg 67046-0236-03 Coupler 30 tablets — AB FDA listed —
Glipizide 5 mg 71335-2520-01 Bryant 100 tablets — AB FDA listed —
Glipizide 5 mg 72789-0130-30 PD-Rx 30 tablets — AB FDA listed —
Glipizide 5 mg 50090-0502-00 A-S 30 tablets — AB FDA listed —
Glipizide 5 mg 50090-6975-00 A-S 90 tablets — AB FDA listed —
Glipizide 5 mg 68071-4857-01 NuCare 100 tablets — AB FDA listed —
Glipizide 5 mg 72162-2103-00 Bryant 1000 tablets — AB FDA listed —
Glipizide 5 mg 68788-4178-01 Preferred 100 tablets — AB FDA listed —
Glipizide 5 mg 11788-0117-01 AiPing 100 tablets — AB FDA listed —
Glipizide 5 mg 72789-0579-30 PD-Rx 30 tablets — AB FDA listed —
Glipizide 5 mg 64980-0696-01 Rising 100 tablets — AB FDA listed —
Glipizide 5 mg 50090-8178-00 A-S 30 tablets — AB FDA listed —
About this product: other versions of the same ingredient, strength and form are listed above, least expensive first, with FDA equivalence ratings where available.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2017
Listed with the FDA since
May 2017
📍
2026
Currently FDA-listed
9 years listed
🔓
·
Generic versions listed
see equivalents
✅Generic appears available

FDA-approved generic versions are listed, and recent pricing/market data suggests they may be available — see Therapeutic equivalents.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

🧪 Avoiding an ingredient? See Glipizide inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.

Loading inactive ingredients from the official FDA label in the background. No external source is being called by this page request.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerPiramal Pharma Limited
Labeler code66112
First marketedMay 2017
Product typeDrug For Further Processing
Portfolio61 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full FDA label FDA SPL

The complete FDA label for this product, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
📄 FDA label 19 words ▾

No FDA label is on file for this product yet. Labels load from openFDA / DailyMed and refresh weekly.

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Glipizide (matched by generic name) — the program that covers self-administered drugs. 8 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Glipizide. CMS lists 4 products for this generic; we show the highest-spend one. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$13.01M
Claims incl. refills
1.1M
Beneficiaries
795.9K
Spend / beneficiary
$16.34
Spend / claim
$12.36
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Glipizide — the ingredient across all brands.

Top reported reactions

Blood Glucose Increased6,727
Nausea4,586
Diarrhoea3,425
Fatigue3,081
Weight Decreased2,839
Dizziness2,494
Dyspnoea2,464

Age at onset

Neonate1
Infant3
Child4
Adolescent3
Adult3,071
Elderly4,204

Reporter sex

61,089 reports
Male · 49%
Female · 51%
Unknown · 0%

Serious outcomes

Hospitalization18,277
Death5,364
Life-threatening1,488
Disabling1,293
Reports over time (by year) — tap or hover for the count & year
2019 2021 2023 2026 4,045 1,340
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.

About this NDC listing & data coverage

Listed for further processing / repackaging

What "drug for further processing" means

FDA lists this package under the "drug for further processing" marketing category: Piramal Pharma Limited supplies it to other companies for further processing or repackaging (blister cards that are later repackaged or co-packaged are a common example). The units themselves are a finished dosage form — which is why pricing or Medicaid data can still appear — but this exact package code may not be the presentation a retail pharmacy dispenses.

What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) ✓ Available
Package photos — Not published for this NDC No photo available yet for this listing.
Inactive ingredients (structured) — Not published for this NDC The labeler did not submit a structured excipient list, or no SPL is available.
NADAC pharmacy acquisition price (CMS) — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey.
Orange Book / therapeutic-equivalence data — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope.
HCPCS J-code billing crosswalk — Not published for this NDC Most self-administered / retail products have no J-code — that is normal.
Medicaid utilization (CMS SDUD) — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold.
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Is this NDC FDA-approved?
An NDC listing does not by itself establish FDA approval — the NDC Directory records that a product is listed with FDA, not that it was reviewed and approved. This listing's marketing category is "Drug For Further Processing". Products approved under an application carry an NDA, ANDA, or BLA number.
Why is there no price listed?
The pricing shown on our NDC pages comes from CMS NADAC, a voluntary survey of retail community pharmacy invoices. CMS does not publish a NADAC for every NDC — packages outside the retail survey (institutional and hospital products, bulk packages, discontinued items, and many OTC items) may never receive one. A missing price reflects the survey's scope, not this product's actual cost, and does not mean the product is free or unavailable.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The form printed on the packaging and shown on DailyMed is the one the FDA registered. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero and the dashes are dropped. The Identity section at the top of this page lists each form of this code.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by Piramal Pharma Limited. Listing status can change — the directory data on this page refreshes weekly.
Does this product come in other package sizes?
Yes — the FDA directory lists 3 other package presentations of this same product, including 100 tablets (66112-0914-01), 500 tablets (66112-0914-02), 1000 tablets (66112-0914-03). Each has its own NDC and its own page — see the package list near the top of this page.
Who lists this product with the FDA?
Piramal Pharma Limited is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.